Effects of the Insulin-Sensitizing Drug Pioglitazone and Lipopolysaccharide Administration on Insulin Sensitivity in Horses
Autor: | J. K. Suagee, J.G. Wearn, Raymond J. Geor, Laura Jill McCutcheon, Matthew W. Hulver, Benjamin A. Corl, Mark V. Crisman |
---|---|
Rok vydání: | 2011 |
Předmět: |
medicine.medical_specialty
General Veterinary biology business.industry Insulin medicine.medical_treatment Adipose tissue Laminitis medicine.disease Insulin receptor Insulin resistance Endocrinology Oral administration Internal medicine medicine biology.protein business Pioglitazone GLUT4 medicine.drug |
Zdroj: | Journal of Veterinary Internal Medicine. 25:356-364 |
ISSN: | 0891-6640 |
DOI: | 10.1111/j.1939-1676.2011.0681.x |
Popis: | BACKGROUND Obesity and insulin resistance increase the risk of laminitis in horses. Pioglitazone (PG) is an insulin-sensitizing drug used in humans that is absorbed after oral administration to horses. HYPOTHESIS PG treatment will increase insulin sensitivity and transcript abundance of glucose and lipid transporters in adipose and skeletal muscle tissues. ANIMALS Sixteen lean, healthy horses. METHODS Eight horses were administered PG (1 mg/kg bodyweight PO) for 12 days before induction of insulin resistance through IV administration of lipopolysaccharide (LPS). Treated and untreated controls (CN; n = 8) were subjected to testing of peripheral insulin sensitivity and biopsies of both subcutaneous (nuchal ligament) adipose tissue and skeletal muscle before and after treatment, and 24 hours after LPS administration. RESULTS PG treatment did not improve basal insulin sensitivity (CNs: 1.4 ± 0.3, PG-treated: 1.9 ± 1.3; P > .4) or mitigate LPS-induced insulin resistance (CNs: 0.4 ± 0.3, PG-treated: 0.4 ± 0.3); however, transcript abundance of glucose and lipid transporters was altered in both skeletal muscle and subcutaneous adipose tissue. CONCLUSIONS AND CLINICAL IMPORTANCE Either a higher dose or longer treatment period might be required for physiological effects to be observed. PG is a novel therapeutic agent requiring further investigation in horses in order to determine treatment efficacy. |
Databáze: | OpenAIRE |
Externí odkaz: |